|Product Candidate / PROGRAM||Drug substance||Indication||Discovery||Pre-clinical||Phase 1||Phase 2||Phase 3/ Pivotal||Commercial Rights|
|eryaspase (GRASPA® (1))||Asparaginase||PDAC 2L|
|Solid tumor TBD|
ERYTECH’s lead product candidate eryaspase, L-asparaginase encapsulated inside a donor-derived red blood cell, is a novel product candidate aimed at targeting cancer cells’ altered amino acid metabolism. L-asparaginase is well-established in the treatment of acute lymphoblastic leukemia, but toxicity has prevented its use in the most fragile patients and in other indications.
By encapsulating the L-asparaginase into red blood cells, eryaspase aims to enlarge its therapeutic window, and broaden the scope to other oncology indications such as pancreatic cancer and triple-negative breast cancer.